Mumbai : Bearing in mind the most important challenge at present in oncology which is to develop affordable and cost-effective therapies, health experts from the oncology field present at Tata Memorial Hospital (TMH) on Wednesday stated that ‘Metronomics’ which is the science of using low dose, continuous treatment for treatment of cancer is a relatively new branch in oncology which will be very useful for patients in India.
In wake of this, a press conference will be held at Tata Memorial Hospital from Friday to Sunday which will be covering all aspects of metronomic therapy starting from its biology, approach, clinical practice, current trends and future prospects. The conference will include more than 350 delegates from India and across the world and more than 15 International Faculty members including Dr Robert Kerbel, Canada, who is considered the “father” of metronomic therapies.
Dr Sripad Banavali, head of department of paediatric oncology of TMH said, “By 2050, 27 million new cancer cases will be diagnosed worldwide. This can lead to 17.5 million cancer deaths or 50,000 cancer deaths a day. Even after waging the “War against Cancer” for years, most of the advanced cancers, especially in adult patients, are still not curable. The most important challenge at present in oncology is to develop affordable, cost-effective therapies. In this context, the silent revolution of “Metronomic” chemotherapies is slowly sweeping across the globe.”